~~<i id='3F186C853D'><strike id='3F186C853D'><tt id='3F186C853D'><pre id='3F186C853D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

hotspot

author：Wikipedia 2025-10-02 10:45:51 - browse：86

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Sanders adds drug shortage policies to pandemic preparedness bill

explore

leisure time

hotspot

leisure time

focus

ChristineKao/STATUnitedHealthGroupquietlyacquireddozensofoutpatientfacilitiesin2023,withaparticularf

WSS

Change Healthcare cyberattack prompts Medicare loan program

RSV shot was 90% effective at preventing hospitalizations in kids

Change Healthcare payments predicted restored March 15

In early work, researchers turn to CRISPR to treat Alzheimer's

Custom gene therapy hints at new path for rare disease treatments

Precocious puberty in girls comes with mental health risks

explore

hotspot

explore

23andMe had bad news about my health. I wish a person had delivered it

Medicare to cover more brain scans for Alzheimer’s patients

Wildfire smoke exposes gaps in outdoor worker protections

Cosmetics set for new safety regulation. Why the industry is on board

New air purifier tech could be key to improving indoor air quality

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Tori Bowie and the unacceptable rates of Black maternal death

Headspace, Meta partner to launch VR meditation app for Quest

Alkermes shareholders re

Listen: Wegovy in the brain & pivotal Alzheimer's data

leisure time

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Group opposing PBM reform sets lobbying record

Startup Neumora takes a novel depression drug to Phase 3

The problem with charging patients to message their doctors

STAT Virtual Event: The State of Biosimilars: What to Watch

leisure time

hotspot

leisure time

focus